Company Focus
Bristol Myers Squibb
Latest Bristol Myers Squibb News
Pharmaceutical
Bristol Myers Squibb has posted better-than-expected second-quarter 2025 results, driven by strong sales of its blood thinner Eliquis (apixaban) and cancer treatments Opdivo (nivolumab) and Revlimid (lenalidomide). 31 July 2025
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.
Latest News & Features of interest to Bristol Myers Squibb
Pharmaceutical
Pfizer posted second-quarter 2025 earnings and revenue that exceeded analyst estimates and raised its full-year profit outlook, pushing its shares higher by 4% in Tuesday morning’s trading. 5 August 2025
Pharmaceutical
US biopharma Vertex Pharmaceuticals has reported its financial results for the second quarter of 2025 and reiterated full year financial guidance. 5 August 2025
Biotechnology
US cardiometabolic specialist MetaVia has announced a research collaboration with Korea’s Syntekabio, an artificial intelligence (AI)-driven drug discovery company. 5 August 2025
Biotechnology
Japanese drugmaker Sumitomo Pharma Company and Tokyo-based Racthera announced that on August 5, they had submitted an application of manufacturing and marketing authorization for allogeneic iPS cell-derived dopaminergic neural progenitor cells (generic name: raguneprocel) indication of the improvement of motor functions during the off-time period of patients with advanced Parkinson’s disease. 5 August 2025
Biotechnology
XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday. 5 August 2025
Biotechnology
Privately-held US clinical-stage biotech Cellergy Pharma announced the appointment Christopher Cano as chief executive (CEO). 5 August 2025
Biotechnology
Germany’s BioNTech has reported revenues for the second quarter 2025 of 260.8 million euros ($302 million), more than double the 128.7 million euros of the same period in 2024 and way above the consensus estimate of €137.9 million euros. 4 August 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), extending its use as monotherapy along with diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. 4 August 2025
Biosimilars
Biosimilars, once met with skepticism, are now an undeniable force in the global pharmaceutical market. As several blockbuster biologics lose exclusivity, biosimilars are stepping in to capture market share and drive savings for healthcare systems worldwide. 4 August 2025
Biotechnology
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla (donanemab-azbt) continued to demonstrate slowing of decline, with most participants having completed treatment, US pharma major Eli Lilly announced today. 4 August 2025
Latest In Brief for Bristol Myers Squibb
Biotechnology
US biotech Nanoscope Therapeutics has begun a rolling submission to the American medicines regulator for MCO-010, the first gene-agnostic therapy seeking approval for retinitis pigmentosa (RP). 15 July 2025
Latest Relevant Ones To Watch News
XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday. 5 August 2025
18 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze